FZI Mainz: Translational Research Project: “Regulation of Autoimmunity via Oral Wheat alpha-Amylase Trypsin Inhibitors”. Role: PI, with Prof. A. Waisman, Institute for Translational Medicine: 07/01/2014 – 06/30/2016. http://www.fzi.uni-mainz.de/42_DEU_HTML.php
Boehringer-Ingelheim: “Mechanistic and Therapeutic Studies for non-Alcoholic Steatohepatitis (NASH)”. Role: PI: 09/01/2012 – 08/31/2015.
Foundation Rhineland-Palatinate for Innovation: “Development of Serum Markers for the Assessment of Liver Fibrosis Progression and Reversal”. Role: PI: 09/01/2013 – 08/31/2015.
German Ministry of Education and Research (BMBF), CI3 Cluster for Individualized Immune Intervention (with Zedira Pharma, Falk Pharma): “Clinical Development of Transglutaminase-Inhibitors for the Treatment of Celiac Disease”. Phase 1. Role: Co-PI: 04/01/2012 – 06/30/2015.
Boehringer Ingelheim: “Evaluation of anti-fibrotic effect of three anti-fibrotic compounds in experimental biliary and panlobular liver fibrosis”. Role: PI: 01/12/2012 – 01/31//2015.
NIH 1R21DK075857-01A2. Title: “Fibrolytic activation of hepatic stellate cells by T cell derived microparticles”. Role: PI: 10/01/2009 – 09/31/2011.
NIH U01AT003571-01. Title: “Evaluation of Silymarin in chronic liver diseases”. Role: Co-PI: 6/15/2006-6/14/2011.
NIH U19 AI066313. Hepatitis C Cooperative Research Centers: Title: “Mechanisms of HCV induced Liver Fibrosis”. Role: PI of center grant, PI of subproject #3: 03/01/2005-02/28/2011.
NIH 1R21AI078385A1-01. Title: “Characterization of innate immune receptors for gluten in celiac disease”. Role: PI: 09/01/2008-08/30/2010.
NIH 1R21A1 DK076873-01. Title: “Identification of serum markers of liver fibrogenesis/fibrolysis by proteomics”. Role: PI; 07/01/2007-06/30/2010.
Cystic Fibrosis Foundation Research Grant. Title: “Mouse model for cystic fibrosis liver disease”. Role: PI; 04/01/2008-03/31/2010.